Elegen, a leading provider of DNA synthesis and production solutions, announced the successful completion of a $35 million Series B funding round. The investment, led by Triatomic Capital, signifies a significant milestone in Elegen’s mission to revolutionize DNA synthesis technology.
Joining Triatomic Capital in the funding round are prominent investors such as GSK and John Ballantyne, co-founder of Aldevron, as well as existing investors including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures, and Agilent Technologies. Peter Zhou, General Partner of Triatomic Capital, will also join Elegen’s board, bringing valuable expertise and insights to the company.
The capital infusion will fuel Elegen’s efforts to expand its ENFINIA™ DNA product line across clinical workflows, catering to the growing demand for GMP-compliant DNA in the development of genetic medicines. Leveraging its proprietary microfluidics approach, Elegen aims to accelerate upstream discovery processes and streamline the deployment of new clinical modalities in industries such as agriculture, chemicals, healthcare, and pharmaceuticals.
Founded in 2017 by Matthew Hill, Ph.D., and CEO, Elegen has emerged as a trailblazer in DNA synthesis technology, offering faster and more efficient solutions to meet the evolving needs of various industries. With a commitment to innovation and technical excellence, Elegen is well-positioned to drive advancements in DNA synthesis and contribute to the development of groundbreaking genetic medicines.
Matthew Hill, CEO of Elegen, expressed enthusiasm about the investment, stating, “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”
As Elegen embarks on its next phase of growth and innovation, the company remains dedicated to delivering cutting-edge solutions that empower researchers and clinicians to unlock the full potential of genetic medicine.
